Stock Scorecard

Stock Summary for Affimed N.V. (AFMD) - $0.83 as of 5/5/2025 4:43:10 PM EST

Total Score

11 out of 30

Safety Score

25 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AFMD

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AFMD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AFMD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AFMD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AFMD (25 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AFMD

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting 4/29/2025 2:00:00 PM
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting 4/23/2025 2:05:00 PM
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement 4/21/2025 10:30:00 AM
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting 3/25/2025 8:30:00 PM
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 3/3/2025 11:30:00 AM
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia ( R/R AML ) 12/9/2024 6:30:00 PM
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer 12/9/2024 11:30:00 AM
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma ( R/R cHL ) Patients 12/8/2024 5:00:00 PM
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy 12/6/2024 3:36:00 PM
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy ( RMAT ) Designation by the U.S. Food and Drug Administration ( FDA ) 12/5/2024 11:30:00 AM

Financial Details for AFMD

Company Overview
Ticker AFMD
Company Name Affimed N.V.
Country USA
Description Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 6/9/2025

Stock Price History
Last Day Price 0.83
Price 4 Years Ago 55.20
Last Day Price Updated 5/5/2025 4:43:10 PM EST
Last Day Volume 124,787
Average Daily Volume 125,690
52-Week High 8.95
52-Week Low 0.52
Last Price to 52 Week Low 59.62%

Valuation Measures
Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE -48.52
Free Cash Flow Ratio 1.84
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 1.93
Total Cash Per Share 0.45
Book Value Per Share Most Recent Quarter 1.05
Price to Book Ratio 0.81
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 2.79
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 16,392,300
Market Capitalization 13,605,609
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -23.18%
Reported EPS 12 Trailing Months -5.15
Reported EPS Past Year -3.22
Reported EPS Prior Year -1.92
Net Income Twelve Trailing Months -65,216,000
Net Income Past Year -105,938,000
Net Income Prior Year -86,004,000
Quarterly Revenue Growth YOY -91.60%
5-Year Revenue Growth -19.00%
Operating Margin Twelve Trailing Months -8,709.00%

Balance Sheet
Total Cash Most Recent Quarter 7,405,000
Total Cash Past Year 38,529,000
Total Cash Prior Year 190,286,000
Net Cash Position Most Recent Quarter 5,174,000
Net Cash Position Past Year 32,210,000
Long Term Debt Past Year 6,319,000
Long Term Debt Prior Year 11,687,000
Total Debt Most Recent Quarter 2,231,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.89
Total Stockholder Equity Past Year 57,807,000
Total Stockholder Equity Prior Year 152,915,000
Total Stockholder Equity Most Recent Quarter 17,195,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -68,015,000
Free Cash Flow Per Share Twelve Trailing Months -4.15
Free Cash Flow Past Year -113,998,000
Free Cash Flow Prior Year -105,588,000

Options
Put/Call Ratio 0.02
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.05
MACD Signal 0.01
20-Day Bollinger Lower Band 0.58
20-Day Bollinger Middle Band 0.97
20-Day Bollinger Upper Band 1.37
Beta 2.07
RSI 58.02
50-Day SMA 8.36
150-Day SMA 0.00
200-Day SMA 19.24

System
Modified 5/5/2025 4:43:11 PM EST